Application of Baatimatat to preparation of medicine for preventing and treating obesity and secondary bone loss

A technology for bone loss and obesity, applied in the field of medicine

Inactive Publication Date: 2021-07-23
SUZHOU UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Batimastat was originally developed as an anti-tumor (especially anti-tumor metastasis) drug, but its effects in anti-obesity, regulation of glucose metabolism in vivo, and alleviation of bone loss in obesity have not yet been reported.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Baatimatat to preparation of medicine for preventing and treating obesity and secondary bone loss
  • Application of Baatimatat to preparation of medicine for preventing and treating obesity and secondary bone loss
  • Application of Baatimatat to preparation of medicine for preventing and treating obesity and secondary bone loss

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1: Batimastat relieves obesity caused by high-fat diet

[0033] (1) Establishment of high-fat diet obesity model

[0034] Twenty-four 6-week-old male C57BL / 6 mice were randomly divided into 3 groups, 8 in each group, as control diet group (Ctrl), high-fat diet group (HFD) and high-fat diet BB-94 intervention group (HFD +BB-94). Among them, the control group was fed with purified 10% fat for energy, and the high-fat diet group and high-fat diet BB-94 intervention group were fed with purified 60% fat for energy with high-fat diet. After starting to replace the purified feed for modeling, the mice in the high-fat diet BB-94 intervention group were intraperitoneally injected with BB-94 every 2 days (using the pre-prepared 6 mg / mL Batimastat solution for intraperitoneal injection, 50 μL / 10 g for injection, so that the final The dosage is 30 mg / kg), and the mice in the control group and the high-fat diet group are injected intraperitoneally with the same amount of c...

Embodiment 2

[0037] Example 2: Batimastat alleviates glucose metabolism disorder caused by high-fat diet

[0038] (1) Batimastat relieves impaired glucose tolerance in mice fed a high-fat diet ( image 3 )

[0039] In order to study the effect of BB-94 on the glucose tolerance of obese mice induced by high-fat diet, we used intraperitoneal glucose tolerance test (IPGTT) at the 16th week after modeling to evaluate the mice after HFD modeling. Changes in glucose tolerance and the effect of BB-94 intervention. At the 16th week after the high-fat diet obesity model was established, the mice in each group were fasted for 8 hours (removing food and keeping drinking water) for intraperitoneal glucose tolerance test. D-(+)-glucose was dissolved in sterilized PBS to prepare a 0.1 g / mL glucose solution, which was injected intraperitoneally at a dose of 100 μL / 10 g (the final dose was 1 g / kg). Collect tail vein blood at 0, 15, 30, 60, and 120 minutes respectively, using Roche The Active blood gl...

Embodiment 3

[0044] Example 3: Effect of Batimastat on white adipose tissue in various parts of obese mice with high-fat diet

[0045] (1) Batimastat alleviated the accumulation of white adipose tissue in the abdominal cavity of mice fed a high-fat diet ( Figure 5 )

[0046] On the basis of the previous study on the effects of BB-94 on body weight, glucose metabolism disorder, and insulin resistance in obese mice fed a high-fat diet, we further evaluated its effect on white adipose tissue in various parts of obese mice fed a high-fat diet by gross morphology and histological staining. influences. First of all, when the mice were collected, a large amount of white fat accumulation (epididymal white adipose tissue) could be observed in the abdominal cavity of the mice in the HFD group after opening the abdominal cavity, while this situation was significantly improved in the mice in the HFD+BB-94 group.

[0047] (2) Batimastat alleviated the hypertrophy and hypertrophy of white adipose tis...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of Baatimatat to preparation of a medicine for preventing and treating obesity and secondary bone loss. According to the invention, a mouse high-fat diet obesity model is utilized to simulate the most common primary obesity in people; the in-vivo biological efficacy of the Batimatat is evaluated through multiple dimensions such as weight, glycometabolism, adipose tissue change, bone metabolism and the like; the fact that the Batimatat can be applied to prevention and treatment of obesity caused by over-differentiation and accumulation of adipocytes and concomitant complications of glucose metabolic disorders, osteopenia and the like is defined for the first time; and the Batimatat takes a relatively remarkable effect.

Description

technical field [0001] The invention relates to the application of Batimastat in the preparation of medicines for preventing and treating obesity and secondary bone loss, and belongs to the technical field of medicine. Background technique [0002] In recent decades, with the improvement of people's living standards and changes in population structure, diet and living habits, the number of overweight / obese people in my country has been increasing day by day. Two recent epidemiological studies have shown that the adult overweight / obese rates are as high as 30.6% and 32.3%. . In addition, the overweight / obesity rate in the United States will exceed 50% in 2030, resulting in a loss of $549.5 billion in the medical field alone. The basic feature of obesity is that the ability to absorb more than the body's required capacity causes the number of fat cells in the body to increase (Hyperplasia) and the volume to increase (Hypertropy), leading to excessive accumulation of body fat, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/381A61P3/04A61P19/08
CPCA61K31/381A61P3/04A61P19/08
Inventor 陈建权章礼炜
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap